These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 24344941)
1. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant. Soliman AR; Fathy A; Khashab S; Shaheen N; Soliman MA Exp Clin Transplant; 2013 Dec; 11(6):494-8. PubMed ID: 24344941 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience. Sudhakaran C; Kishore U; Anjana RM; Unnikrishnan R; Mohan V Diabetes Technol Ther; 2011 Jan; 13(1):27-32. PubMed ID: 21175268 [TBL] [Abstract][Full Text] [Related]
3. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes. Giampietro O; Giampietro C; Bartola LD; Masoni MC; Matteucci E Drug Des Devel Ther; 2013; 7():99-104. PubMed ID: 23439744 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P; Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236 [TBL] [Abstract][Full Text] [Related]
5. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Aschner P; Chan J; Owens DR; Picard S; Wang E; Dain MP; Pilorget V; Echtay A; Fonseca V; Lancet; 2012 Jun; 379(9833):2262-9. PubMed ID: 22683131 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Charbonnel B; Karasik A; Liu J; Wu M; Meininger G; Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study. Seufert J; Pegelow K; Bramlage P Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985 [TBL] [Abstract][Full Text] [Related]
9. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. Srivastava S; Saxena GN; Keshwani P; Gupta R J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111 [TBL] [Abstract][Full Text] [Related]
10. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes. Gallwitz B Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea. Liu SC; Chien KL; Wang CH; Chen WC; Leung CH Endocr Pract; 2013; 19(6):980-8. PubMed ID: 23807528 [TBL] [Abstract][Full Text] [Related]
12. [Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes]. Scheen AJ; Van Gaal LF Rev Med Liege; 2010 Mar; 65(3):127-32. PubMed ID: 20411816 [TBL] [Abstract][Full Text] [Related]
13. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Katsuno T; Ikeda H; Ida K; Miyagawa J; Namba M Endocr J; 2013; 60(6):733-42. PubMed ID: 23386390 [TBL] [Abstract][Full Text] [Related]
14. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. Yang W; Guan Y; Shentu Y; Li Z; Johnson-Levonas AO; Engel SS; Kaufman KD; Goldstein BJ; Alba M J Diabetes; 2012 Sep; 4(3):227-37. PubMed ID: 22672586 [TBL] [Abstract][Full Text] [Related]
15. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Kim HS; Shin JA; Lee SH; Kim ES; Cho JH; Son HY; Yoon KH Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737 [TBL] [Abstract][Full Text] [Related]
16. Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes. Asai S; Ohta A; Kato H; Sada Y; Nagai Y; Kondo A; Sasaoka T; Tanaka Y Endocr J; 2014; 61(12):1213-20. PubMed ID: 25231694 [TBL] [Abstract][Full Text] [Related]
17. Managed care perspective on three new agents for type 2 diabetes. VanDeKoppel S; Choe HM; Sweet BV J Manag Care Pharm; 2008 May; 14(4):363-80. PubMed ID: 18500914 [TBL] [Abstract][Full Text] [Related]
18. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus. Chwieduk CM Drugs; 2011 Feb; 71(3):349-61. PubMed ID: 21319871 [TBL] [Abstract][Full Text] [Related]
19. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Strøm Halden TA; Åsberg A; Vik K; Hartmann A; Jenssen T Nephrol Dial Transplant; 2014 Apr; 29(4):926-33. PubMed ID: 24452849 [TBL] [Abstract][Full Text] [Related]
20. Sitagliptin: a novel drug for the treatment of type 2 diabetes. Choy M; Lam S Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]